Score Overview
Explore the 2021 public Archive ranking →
Where Gilead Sciences Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- GILD
2003: 50.3% · 2021: 59.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 152.21 | — |
1 Year2025-09-26 | $ 109.40 | 39.14% |
5 Years2021-09-28 | $ 58.56 | 159.94% |
10 Years2016-09-28 | $ 55.44 | 174.54% |
20 Years2006-09-28 | $ 11.71 | 12x |
30 Years1996-09-27 | $ 0.58 | 261x |
All Time1992-01-22 | $ 0.43 | 352x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1992-01-22 |
|---|---|---|---|---|---|---|---|
| Price | $ 152.21 | $ 109.40 | $ 58.56 | $ 55.44 | $ 11.71 | $ 0.58 | $ 0.43 |
| Return | — | 39.14% | 159.94% | 174.54% | 12x | 261x | 352x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 30.45B | -$ 3.24B | $ 3.17B |
| 2025 | $ 29.44B | $ 8.51B | $ 9.61B |
| 2024 | $ 28.75B | $ 480M | $ 11.56B |
| 2023 | $ 27.11B | $ 5.66B | $ 7.26B |
| 2022 | $ 27.28B | $ 4.59B | $ 6.38B |
| 2021 | $ 27.30B | $ 6.22B | $ 6.52B |
| 2020 | $ 24.68B | $ 123M | $ 7.40B |
| 2019 | $ 22.44B | $ 5.38B | $ 24.35B |
| 2018 | $ 22.12B | $ 5.45B | $ 30.08B |
| 2017 | $ 26.10B | $ 4.62B | $ 25.51B |
| 2016 | $ 30.39B | $ 13.50B | $ 32.38B |
| 2015 | $ 32.63B | $ 18.10B | $ 26.20B |
| 2014 | $ 24.89B | $ 12.10B | $ 11.72B |
| 2013 | $ 11.20B | $ 3.07B | $ 2.13B |
| 2012 | $ 9.70B | $ 2.59B | $ 1.86B |
| 2011 | $ 8.38B | $ 2.80B | $ 9.90B |
| 2010 | $ 7.94B | $ 2.90B | $ 2.09B |
| 2009 | $ 7.01B | $ 2.63B | $ 1.65B |
| 2008 | $ 5.33B | $ 1.97B | $ 1.79B |
| 2007 | $ 4.23B | $ 1.61B | $ 1.17B |
| 2006 | $ 3.02B | -$ 1.18B | $ 936M |
| 2005 | $ 2.02B | $ 813M | $ 2.31B |
| 2004 | $ 1.32B | $ 449M | $ 1.25B |
| 2003 | $ 867M | -$ 72M | $ 707M |
| 2002 | $ 466M | $ 72M | $ 942M |
| 2001 | $ 233M | $ 52M | $ 582M |
| 2000 | $ 195M | -$ 56M | $ 512M |
| 1999 | $ 169M | -$ 66M | $ 294M |
| 1998 | $ 151M | -$ 44M | $ 101M |
| 1997 | $ 132M | -$ 72M | $ 32M |
| 1996 | $ 33M | -$ 21M | $ 132M |
| 1995 | $ 2M | -$ 27M | $ 27M |
| 1994 | $ 4M | -$ 31M | $ 30M |
| 1993 | $ 4M | -$ 25M | $ 13M |
| IPO1992 | $ 4M | -$ 14M | $ 2M |
Gilead Sciences Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 2.02B to $ 29.44B and net income grew from $ 813M to $ 8.51B. Revenue increased in 15 of those 20 years; net income in 11.
Between 1995 and 2025, revenue grew from $ 2M to $ 29.44B and net income went from -$ 27M to $ 8.51B. Revenue increased in 25 of those 30 years; net income in 17.
Gilead Sciences Inc currently holds a 20-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.
Membership
Continue GILD’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
